IndustryCompany release

Quantum Biopharma narrows nine-month net loss to $17.3M as cash and digital assets rise

Quantum Biopharma Ltd. (QNTM) · Thu 12 Nov 2026

The company formerly known as FSD Pharma reports a smaller loss for the nine months to September 2026, with cash near $3.6M and digital assets near $8.7M.

Quantum Biopharma Ltd., formerly FSD Pharma, has published unaudited condensed interim financial statements for the three and nine months ended 30 September 2026. The company reported a net loss of about $17.3M for the nine-month period, compared with $23.3M a year earlier.

The narrower loss reflects lower operating expenses and smaller fair-value losses on derivatives and warrants, according to the company's summary of the results.

The balance sheet strengthened over the period. Cash rose to about $3.6M and digital assets increased to about $8.7M. The company attributes this to roughly $10.3M of net proceeds from share issuance and $2.7M raised through convertible debentures.

The material available for this report was limited to a summary of the results. It did not include detail on the three-month figures, the composition of operating costs, or the status of the company's clinical programmes.

What it means for your team

  • Quantum Biopharma continues to rely on equity and convertible debt financing rather than operating income, a factor partners and counterparties may weigh when assessing the company.
  • Digital assets now form a sizeable share of the company's reported holdings relative to cash, so the balance sheet may be sensitive to market valuation movements.
  • Teams tracking the company's development programmes should consult the full interim statements for programme-level spending and funding runway, as the summary does not provide them.

Company's press release (SEC filing): Quantum Biopharma Ltd. ↗

Article written by VigiEye from the official source (Quantum Biopharma Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →